$0.46
+0.00 (+0.52%)
Open$0.48
Previous Close$0.46
Day High$0.49
Day Low$0.38
52W High$40.39
52W Low$31.92
Volume—
Avg Volume731.5K
Market Cap1.68M
P/E Ratio35.02
EPS$1.00
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+8,133.6% upside
Current
$0.46
$0.46
Target
$37.99
$37.99
$25.94
$37.99 avg
$62.46
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 261.9K | 257.5K | 229.4K |
| Net Income | -16,622 | -16,876 | -13,616 |
| Profit Margin | -6.4% | -6.6% | -5.9% |
| EBITDA | -23,157 | -21,131 | -19,685 |
| Free Cash Flow | -18,370 | -13,268 | -16,406 |
| Rev Growth | -9.5% | +2.0% | +15.5% |
| Debt/Equity | 0.33 | 0.31 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |